November 22, 2010 - Profil Institute Expands Its Cardiometabolic Capabilities for Diabetes and Obesity Clinical Drug Trials – Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company’s early phase diabetes and obesity clinical trials."Assessing cardiac safety is a critical early objective for the evaluation of new drugs, particularly in compounds for the treatment of diabetes," said Robert J. Schott, a cardiologist and Director of Cardiometabolic Research at the Profil Institute for Clinical Research. "At Profil Institute we are excited to be implementing new technologies and procedures which allow us to assess cardiac safety signals in Phase I drug research, specifically in our ability to detect a drug's risk for causing sudden cardiac death with prolongation of the QT interval as a marker. We understand that detection of cardiac safety signals is mission-critical in early drug development, and new technologies allow us to do this in a more cost-effective and timely manner for our customers."... [PDF] Profil™ Institute for Clinical Research's Press Release -
